• Indivior + Opiant, Regeneron + CytomX, Rezo, Provention

  • 2022/11/22
  • 再生時間: 6 分
  • ポッドキャスト

Indivior + Opiant, Regeneron + CytomX, Rezo, Provention

  • サマリー

  • A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvals

    Find out more at
    https://LifeScienceTodayPodcast.com

    Story References
    Indivior + Opiant
    Regeneron + CytomX
    Rezo
    Provention

    About the Show
    Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

    続きを読む 一部表示

あらすじ・解説

A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvals

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Indivior + Opiant
Regeneron + CytomX
Rezo
Provention

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

Indivior + Opiant, Regeneron + CytomX, Rezo, Proventionに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。